These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [In high risk for diabetes should drugs be used for prevention? (interview by Dr. Judith Neumaier)]. Hanefeld M MMW Fortschr Med; 2002 Oct; 144(40):12. PubMed ID: 12440285 [No Abstract] [Full Text] [Related]
10. Effect of a multifactorial intervention on mortality in type 2 diabetes. Gaede P; Lund-Andersen H; Parving HH; Pedersen O N Engl J Med; 2008 Feb; 358(6):580-91. PubMed ID: 18256393 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular manifestations of insulin resistance. Chahwala V; Arora R Am J Ther; 2009; 16(5):e14-28. PubMed ID: 19114874 [TBL] [Abstract][Full Text] [Related]
12. [Differences between diabetes mellitus type 2 patients switched and not switched over to insulin treatment after specialist consultation]. Goddijn PP; Meyboom-de Jong B; Feskens EJ; van Ballegooie E; Bilo HJ Ned Tijdschr Geneeskd; 1998 May; 142(18):1023-6. PubMed ID: 9623204 [TBL] [Abstract][Full Text] [Related]
13. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities. Malesker MA Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965 [TBL] [Abstract][Full Text] [Related]
14. [Could oral antidiabetic agents be useful in the management of different types of diabetes and syndromes of insulin resistance in children and adolescents?]. Otto-Buczkowska E; Nowowiejska B; Jarosz-Chobot P; Stańczyk J Przegl Lek; 2009; 66(7):388-93. PubMed ID: 20043582 [TBL] [Abstract][Full Text] [Related]
15. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Resmini E; Minuto F; Colao A; Ferone D Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513 [TBL] [Abstract][Full Text] [Related]
16. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes. Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343 [TBL] [Abstract][Full Text] [Related]
18. Role of lifestyle and oral anti-diabetic agents to prevent type 2 diabetes mellitus and cardiovascular disease. Bethel MA; Califf RM Am J Cardiol; 2007 Mar; 99(5):726-31. PubMed ID: 17317381 [TBL] [Abstract][Full Text] [Related]